ReachRxResearch
Home
Research
Sign Up
γδ T cells modulate anti-tumor immunity in small cell lung cancer
Back to Research Hub
  1. Home
  2. Research Hub
  3. γδ T cells modulate anti-tumor immunity…

γδ T cells modulate anti-tumor immunity in small cell lung cancer

Cancer Cell·September 18Open Access
OncologyPractice changingSmall Cell Lung CancerTranslational Study (Single-Cell Analysis + Preclinical Models + Retrospective Clinical Cohort Analysis)Anti-PD-L1 TherapyBispecific T Cell EngagerBisphosphonateImmune Checkpoint InhibitorAdultTarlatamabAtezolizumabTarlatamabZoledronate

Summary

View source

What was studied

This study investigated γδ T cell infiltration and anti-tumor function in small cell lung cancer (SCLC) using single-cell approaches on patient biospecimens, two clinical trial cohorts, and preclinical models to evaluate γδ T cells as therapeutic targets.

Key findings

High γδ T cell infiltration predicted improved response to anti-PD-L1 immunotherapy in two practice-changing SCLC clinical trials; γδ T cells maintained a cytotoxic transcriptional profile despite PD-1 expression, were effective in tarlatamab (DLL3-CD3 BiTE)-redirected SCLC killing, and zoledronate sensitized SCLC cells to γδ T cell-mediated killing.

Study limitations

Findings from preclinical models may not fully translate to patients; the predictive value of γδ T cell infiltration was assessed retrospectively in clinical trial cohorts; the MHC-I-independent mechanisms driving γδ T cell activity in SCLC require further mechanistic validation.

Clinical implications

γδ T cell infiltration may serve as a biomarker for anti-PD-L1 response in SCLC, and zoledronate (FDA-approved) could be explored as a sensitizing agent to boost γδ T cell-mediated killing in SCLC patients.

Caveats

  • Preclinical efficacy data for tarlatamab-redirected γδ T cell killing and zoledronate sensitization have not yet been validated in prospective clinical trials
  • The paper's publication date is 2026; some referenced 'practice-changing clinical trials' may reflect recently completed studies whose full datasets were not independently verified here
  • The predictive value of γδ T cell infiltration for anti-PD-L1 response was determined by retrospective analysis of clinical trial biospecimens, which may introduce selection bias

Related Questions

Explore related topics

How do γδ T cells recognize and kill MHC-I-negative tumor cells in lung cancer?What is the role of tarlatamab (DLL3-CD3 BiTE) in treating small cell lung cancer?Can zoledronate enhance immune responses to immunotherapy in solid tumors?

Publication Details

Year
2026
Journal
Cancer Cell
Source
View article
Keep scrolling
More content below.
Up Next